Pembrolizumab Before, During, and After Surgery Significantly Improves Survival Outcomes for Head and Neck Cancer Patients, Study Finds
A landmark phase 3 clinical trial led by Dana-Farber Brigham Cancer Center and Washington University School of Medicine has revealed that using the immune checkpoint inhibitor pembrolizumab before, during, and after surgery markedly improves outcomes for patients with locally advanced head and neck cancer. The interim results from the KEYNOTE-689 trial show longer event-free survival and greater tumor shrinkage before surgery compared to the standard treatment protocol.
Historically, treatment for resectable head and neck cancer has relied on surgery followed by radiation and chemotherapy, with only 40–50% of patients surviving beyond five years. Now, after more than two decades, KEYNOTE-689 offers a breakthrough, demonstrating significant improvements over the traditional approach.
“This is a practice-changing study,” emphasized Dr. Robert Haddad, Chief of the Division of Head and Neck Oncology at Dana-Farber and a principal investigator of the study. “Fewer patients needed chemotherapy after receiving pre-surgical immunotherapy, and event-free survival rates have significantly improved.”
The trial enrolled 714 newly diagnosed stage III and IVA head and neck squamous cell carcinoma patients, randomizing them to receive either pembrolizumab plus standard care or standard care alone. Notably, longer event-free survival was observed across all groups, regardless of PD-L1 expression levels. Patients receiving pembrolizumab achieved a median event-free survival of 51.8 months versus 30.4 months for those on standard care alone.
Importantly, pembrolizumab was well tolerated without delaying surgical interventions. Based on these promising results, the FDA is reviewing the regimen for potential approval.
“This is a transformative moment in head and neck cancer care,” said Dr. Ravindra Uppaluri, study chair. “The integration of immunotherapy before surgery highlights the growing importance of multidisciplinary treatment strategies and sets the stage for future innovations.”
